Platelet reactivity is a stable and global phenomenon in aspirin-treated cardiovascular patients

Thrombosis and Haemostasis

Volumn 106, Issue 3, 2011, Pages 466-474

  Zufferey, Anne ^a,b   Reny, Jean Luc ^a   Combescure, Christophe ^a   de Moerloose, Philippe ^a   Sanchez, Jean Charles ^b   Fontana, Pierre ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Aggregation; Aspirin; Atherothrombosis; Platelet

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENE PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CORONARY ARTERY THROMBOSIS; FACTORIAL ANALYSIS; FEMALE; HEREDITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOMENOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; REGULATORY MECHANISM; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; EPINEPHRINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; PRACTICE GUIDELINES AS TOPIC; PROTEOMICS; SEVERITY OF ILLNESS INDEX;

EID: 80052307509     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-04-0226     Document Type: Article

References (48)

1. Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost 2009; 7 (Suppl 1): 258-261
2. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965
3. Breet NJ, van Werkum JW, Bouman HJ, et al. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010; 8: 2140-2148
4. Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2009; 8: 923-933
5. Sofi F, Marcucci R, Gori AM, et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841-848
6. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-739
7. Reny JL, Bonvini RF, Bonvini JM, et al. Poor Responsiveness to Antiplatelet Drugs in Acute Coronary Syndromes: Clinical Relevance and Management. Cardiovasc Ther 2011; in press.
8. Gori AM, Marcucci R, Paniccia R, et al. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost 2008; 100: 1136-1145
9. Yee DL, Sun CW, Bergeron AL, et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005; 106: 2723-2729
10. Yee DL, Bergeron AL, Sun CW, et al. Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 2006; 4: 2043-2050
11. Guthikonda S, Mangalpally K, Vaduganathan M, et al. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thromb Haemost 2008; 100: 83-89
12. Faraday N, Yanek LR, Mathias R, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007; 115: 2490-2496
13. Bray PF, Mathias RA, Faraday N, et al. Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost 2007; 5: 1617-1623
14. Kunicki TJ, Nugent DJ. The genetics of normal platelet reactivity. Blood 2010; 116: 2627-2634
15. Williams MS, Weiss EJ, Sabatine MS, et al. Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arterioscler Thromb Vasc Biol 2010; 30: 2372-2384
16. Jaitner J, Stegherr J, Morath T, et al. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2011; 105: 107-112
17. Peace AJ, Tedesco AF, Foley DP, et al. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J Thromb Haemost 2008; 6: 2027-2034
18. Fontana P, de Moerloose P, Reny JL. Platelet hyperreactivity and dual antiplatelet therapy: can biases be avoided? J Thromb Haemost 2009; 7: 363-364
19. Cazenave JP, Ohlmann P, Cassel D, et al. Preparation of washed platelet suspensions from human and rodent blood. Methods Mol Biol 2004; 272: 13-28
20. Dayon L, Turck N, Kienle S, et al. Isobaric tagging-based selection and quantitation of cerebrospinal fluid tryptic peptides with reporter calibration curves. Anal Chem 2010; 82: 848-858
21. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327
22. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985; 4: 87-90
23. Ohmori T, Yatomi Y, Nonaka T, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006; 4: 1271-1278
24. Gorsuch RL. Factor analysis. 2nd Edition ed, Hillsdale, NJ; 1983.
25. Lanza F, Beretz A, Stierle A, et al. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988; 255: H1276-1288
26. Trip MD, Cats VM, van Capelle FJ, et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554
27. Kabbani SS, Watkins MW, Ashikaga T, et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104: 181-186
28. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 1392-1397
29. Bray PF. Platelet hyperreactivity: predictive and intrinsic properties. Hematol Oncol Clin North Am 2007; 21: 633-645
30. Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-995
31. Dupont A, Fontana P, Bachelot-Loza C, et al. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood 2003; 101: 1833-1840
32. Hetherington SL, Singh RK, Lodwick D, et al. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005; 25: 252-257
33. Jones CI, Garner SF, Angenent W, et al. Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus. J Thromb Haemost 2007; 5: 1756-1765
34. Fontana P, Gandrille S, Remones V, et al. Identification of functional polymorphisms of the thromboxane A2 receptor gene in healthy volunteers. Thromb Haemost 2006; 96: 356-360
35. Jones CI, Bray S, Garner SF, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 2009; 114: 1405-1416
36. O'Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001; 103: 3051-3056
37. Gaxiola B, Friedl W, Propping P. Epinephrine-induced platelet aggregation. A twin study. Clin Genet 1984; 26: 543-548
38. Fontana P, Nolli S, Reber G, et al. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006; 4: 813-819
39. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762
40. Fontana P, Berdague P, Castelli C, et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost 2010; 8: 2614-2623
41. Frelinger AL, 3rd, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase- 1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888-2896
42. Reny JL, De Moerloose P, Dauzat M, et al. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444-450
43. Crescente M, Di Castelnuovo A, Iacoviello L, et al. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost 2008; 99: 1129-1131
44. Geisler T, Gawaz M. Editorial on "Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy" by Marcucci et al. Thromb Haemost 2007; 98: 705-706
45. Marcucci R, Paniccia R, Antonucci E, et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 2007; 98: 844-851
46. Mateos-Caceres PJ, Macaya C, Azcona L, et al. Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients. Thromb Haemost 2010; 103: 160-170
47. Johnson AD, Yanek LR, Chen MH, et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 2010; 42: 608-613
48. Kondkar AA, Bray MS, Leal SM, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010; 8: 369-378.